Further molecular studies indicated that UCHL1 shRNAs treatment remarkably reversed tumor cellular EMT process, which promoted the expression of E-cadherin while reducing the expression level of N-cadherin and vimentin, thus UCHL1 silencing reducing the migrative capability of UBC tumor cells through inhibition of mesenchymal phenotypic transition (Figure 3I, 3J). The gene discussed is UCHL1; the disease is neoplasm.